Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
LBT Innovations Limited ( (AU:CC5) ) has shared an announcement.
Clever Culture Systems Ltd announced the successful passing of all resolutions at their 2025 Annual General Meeting. The resolutions, which included the re-election of a director and approval of securities issuance, were overwhelmingly supported by proxy votes. This outcome reflects strong shareholder confidence and positions the company for continued growth and innovation in the microbiology automation industry.
More about LBT Innovations Limited
Clever Culture Systems (CCS) is a company based in Adelaide, South Australia, specializing in intelligent automation solutions for microbiology laboratories. Their flagship product, the Automated Plate Assessment System (APAS® Independence), utilizes artificial intelligence and machine learning to automate the imaging, analysis, and interpretation of microbiology culture plates. This technology is the only US FDA-cleared AI technology for automated culture plate reading, marketed to pharmaceutical manufacturing and clinical laboratories for environmental monitoring and infectious disease diagnostics. Thermo Fisher Scientific, Inc is the exclusive distributor for clinical customers in the US and select European countries.
Average Trading Volume: 1,952,823
Technical Sentiment Signal: Hold
Current Market Cap: A$65.67M
For a thorough assessment of CC5 stock, go to TipRanks’ Stock Analysis page.